ALTSTATION.IO

Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$88.51

Change

-0.25%

Market Cap

$17.54B

Avg Volume

2.1M

Company Overview

Zimmer Biomet Holdings, Inc. develops and sells medical technology focused on orthopedic and surgical solutions. The company produces a range of products, including knee and hip implants, sports medicine items, and trauma care systems. Their offerings are essential for treating injuries and disorders related to bones and joints. Customers include orthopedic and neurosurgeons, hospitals, and healthcare purchasing organizations.

Zimmer Biomet holds a strong position in the medical device sector, especially in orthopedic reconstructive products. They are a market leader, facing competition from companies like Stryker and Johnson & Johnson. Their edge comes from a robust product portfolio and ongoing innovation, including their development of surgical robots for optimal implant placement. However, they are also challenged by pricing pressures and evolving industry regulations.

Currently, Zimmer Biomet is focusing on growth through innovation and strategic acquisitions. The company recently reported a revenue increase of 15% year-over-year, highlighting a recovery trajectory post-COVID-19. They are also enhancing their product offerings in robotic surgery, which positions them well for the future. This combination of growth momentum and strategic focus provides a solid foundation for Zimmer Biomet as they navigate the competitive landscape ahead.

Key Financials

Market Cap

$17.54B

Revenue

$8.01B

EBITDA

$2.64B

Gross Margin

71.6%

Profit Margin

10.1%

Revenue Growth

9.7%

Total Cash

$1.31B

Total Debt

$8.24B

Free Cash Flow

$1.17B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

21.96

Forward P/E

10.46

Beta

0.61

52-Week High

$114.44

52-Week Low

$84.59

EPS

$4.03

50-Day Avg

$90.68

200-Day Avg

$95.43

Price/Book

1.38

Technical Analysis

The 52-week chart for Zimmer Biomet Holdings, Inc. (ZBH) indicates a generally bearish trend, with a significant decline of 9.6% in the current price of $88.51 from earlier levels. Key support is observed around $85, which has shown resilience during price dips, while the resistance level is marked at approximately $97, where upward momentum has consistently faltered. The chart reflects a potential rounding bottom pattern that suggests a possible reversal if the price can break above the resistance level. Recently, the stock exhibited some bullish momentum, with a series of higher lows, potentially signaling a recovery phase. Currently, the price sits near the low end of the 52-week range, highlighting a cautious outlook for investors, as it suggests limited upside until a clear breakout above resistance occurs.

Recent News and Developments

Zimmer Biomet Holdings, Inc

(ZBH) has been the subject of a legal investigation, observed positive stock price movements, and seen its robotic platform highlighted as crucial for future growth over the past week. The company also has a significant earnings announcement scheduled for early next week.

Market Update

Here are the latest news and developments for ZBH stock in the past week:

### 1

Shareholder Rights Firm Investigates Zimmer Biomet Over Alleged Emerging Market Misrepresentations
On February 4, 2026, national shareholder rights law firm Hagens Berman announced an investigation into Zimmer Biomet Holdings, Inc. concerning potential misrepresentations regarding the stability of its international business. The probe follows disclosures in November 2025 that revealed operational setbacks in emerging markets, including distributor order cancellations and a revenue miss in Latin America, which caused a 15% stock decline at the time. The firm is scrutinizing management’s earlier “high confidence” assurances in August 2025 regarding its 2025 revenue targets.

Market Sentiment and Analyst Recommendations

Bull Case

ZBH is trading at 21.96x P/E with 9.7% revenue growth, which isn’t expensive for a medical device company with recurring procedure-based revenue. The ROSA robotic platform is the real growth engine here—management is betting 2026 on its expansion across knee, hip, and shoulder applications, which is a legitimate competitive moat in orthopedics. The stock has bounced 3.28% in early February and sits at the low end of its 52-week range, suggesting downside is limited around the $85 support level. Analysts see 16% upside to the $102.74 target, and if ROSA adoption accelerates in hospitals and ASCs as expected, the company can deliver the “disciplined acceleration” management promised. The $1.31B cash position and 9.7% revenue growth provide runway to invest in robotics expansion without balance sheet strain.

Bear Case

The emerging markets disaster in Q3 2025 exposed real operational issues—distributor cancellations and a Latin America revenue miss triggered a 15% decline, and now Hagens Berman is investigating whether management misrepresented its confidence in 2025 targets back in August. That’s a credibility hit that matters. The stock is down 9.6% from earlier levels despite the recent bounce, and technical analysis shows consistent resistance at $97 where momentum has failed repeatedly. The $8.24B debt load against $1.31B cash is manageable but not comfortable if ROSA adoption disappoints or if international operations continue deteriorating. The analyst consensus is “hold” across 23 firms—nobody is excited here. With earnings Tuesday morning, there’s real risk that guidance remains cautious after the international stumble.

What to Watch

The Q4 2025 earnings call on February 10 at 8:30 a.m. ET is critical—watch for management’s tone on emerging markets recovery and specific ROSA adoption numbers (procedure volumes, hospital placements, ASC penetration). If they guide 2026 revenue growth above 10% with clear ROSA metrics, the stock rallies toward $97 resistance. If guidance is flat or cautious, it tests the $85 support. Track the Hagens Berman investigation outcome—a settlement or admission of misrepresentation could trigger another leg down. Monitor quarterly ROSA revenue contribution and gross margin impact from mix shift toward robotics. Watch for any distributor or international partnership announcements in the next quarter as evidence of emerging markets stabilization. If the stock breaks above $97 on volume, that rounding bottom pattern completes and targets $110+. Below $85 is a breakdown that signals deeper problems.

Analyst Consensus

HOLD

Based on 23 analyst opinions

Low Target

$86.00

Mean Target

$102.74

High Target

$130.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Devices

Employees

17,000

Earnings & Dividends

Next Earnings

Feb 10, 2026

EPS (Trailing)

$4.03

Dividend Yield

108.0%

Payout Ratio

23.8%

Frequently Asked Questions

Is ZBH a good stock to buy?

ZBH is currently trading at $88.51 with a P/E ratio of 21.96. Analysts recommend a HOLD, with a target price of $102.74, indicating limited upside in the short term.

What is ZBH’s price target?

The current analyst target for ZBH is $102.74. This price suggests a potential upside of around 15.9% from its current price.

Does ZBH pay a dividend?

Yes, ZBH has a dividend yield of 108.0%. This indicates a strong commitment to returning value to shareholders, although investors should verify the sustainability of such a high yield.

What is ZBH’s market cap?

Zimmer Biomet has a market cap of $17.54 billion. This positions it as a significant player in the medical devices sector.

What has been the stock’s performance over the past year?

ZBH’s stock has traded in a 52-week range of $84.59 to $114.44. Currently at $88.51, it’s towards the lower end of that range, suggesting potential buying opportunities if you believe in its long-term growth.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.